Antonio João Roberto, Sanmiguel Jessica, Cagnon Giovana Viotto, Augusto Marília Silveira Faeda, Godoy Moacir Fernandes de, Pozetti Eurides Maria Oliveira
Faculdade Estadual de Medicina de São José do Rio Preto (FAMERP) - São José do Rio Preto (SP), Brazil.
Hospital de Base de São José do Rio Preto - São José do Rio Preto (SP), Brazil.
An Bras Dermatol. 2016 May-Jun;91(3):306-10. doi: 10.1590/abd1806-4841.20164292.
Psoriasis is immune-mediated chronic inflammatory disease with preference for skin and joints. The skin involvement occurs by hyperproliferation and abnormal differentiation of keratinocytes. It is associated with comorbidities, mainly related to the clinical manifestations of the metabolic syndrome. Increased TNF-alpha expression (TNF-α) is related to its pathophysiology. Infliximab is an intravenous drug that acts neutralizing the biological activity of TNF-α and prevents the binding of the molecule to the target cell receptor, inhibiting cell proliferation of psoriasis and other diseases mediated by TNF-α. A lot of infusion reactions have been described in the literature.
To evaluate the adverse effects of intravenous treatment with infliximab, analyzing patients with psoriasis compared to those with other chronic inflammatory diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease and ulcerative colitis).
Analysis of medical records and adverse events of 168 patients undergoing infliximab infusion for psoriasis and chronic inflammatory diseases treatment.
168 patients who have used infliximab were evaluated, 24 had psoriasis and 144 had chronic inflammatory diseases. Only 2 (8.3%) patients with psoriasis showed adverse events requiring treatment discontinuation, and just 6 (4.2%) female patients with chronic inflammatory diseases experienced adverse events.
Infliximab is a safe drug, with a low percentage of adverse events and there were more adverse events in women with chronic inflammatory diseases and in patients who received more infliximab infusions.
银屑病是一种免疫介导的慢性炎症性疾病，好发于皮肤和关节。皮肤受累是由角质形成细胞的过度增殖和异常分化引起的。它与合并症相关，主要与代谢综合征的临床表现有关。肿瘤坏死因子-α（TNF-α）表达增加与其病理生理学相关。英夫利昔单抗是一种静脉用药，其作用是中和TNF-α的生物活性，阻止该分子与靶细胞受体结合，抑制银屑病及其他由TNF-α介导的疾病的细胞增殖。文献中描述了许多输注反应。
评估英夫利昔单抗静脉治疗的不良反应，分析银屑病患者与其他慢性炎症性疾病（类风湿关节炎、强直性脊柱炎、克罗恩病和溃疡性结肠炎）患者的情况。
分析168例接受英夫利昔单抗输注治疗银屑病和慢性炎症性疾病患者的病历及不良事件。
对168例使用英夫利昔单抗的患者进行了评估，其中24例患有银屑病，144例患有慢性炎症性疾病。只有2例（8.3%）银屑病患者出现需要停药的不良事件，只有6例（4.2%）患有慢性炎症性疾病的女性患者出现不良事件。
英夫利昔单抗是一种安全的药物，不良事件发生率低，患有慢性炎症性疾病的女性患者及接受更多次英夫利昔单抗输注的患者不良事件较多。
